These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001246-33 An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207. 2009-03-12 due-trials
Ongoing, reported early 2004-001657-29 A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidence o... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-001658-10 An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treat... 2007-03-20 bad-data
Ongoing 2004-002202-30 An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tubercul... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-004055-19 A Phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subjects. 2011-12-15 bad-data
Completed, but no date, and reported results 2004-004990-27 The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. bad-data
Ongoing 2004-005142-12 An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of TM... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-000594-22 A radomized, controlled, open-label trial to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in treatmet- experienced HIV-1 infected subjects. 2011-10-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000712-27 An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. 2008-08-30 bad-data
Reported results 2005-000793-45 Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options 2007-06-06 due-trials
Reported results 2005-002437-13 Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. 2009-09-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002486-36 A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. 2012-05-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003145-13 A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR ... 2008-08-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003160-32 A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR... 2008-08-01 bad-data
Ongoing, reported early 2005-006179-11 A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatmentexperienced HIV-1 infected children and adolescents. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-001287-23 An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator selected OBR in HIV-1 infected subjects who participated in a DUET trial TMC125-C206 or TMC125-C216 2012-01-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002183-26 A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children. 2008-02-27 bad-data
Completed, but no date, and reported results 2006-002499-16 Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. bad-data
Completed, but no date 2006-003439-53 A double blind, randomized, placebo-controlled study to evaluate the antiviral activity, safety and plasma pharmacokinetics of multiple intravenous doses of TMC353121 in hematopoietic stem cell transp... bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001044-44 A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2b (... 2009-09-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001939-61 A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects... 2011-10-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002646-38 A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricita... 2011-12-15 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002647-25 A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibito... 2012-02-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002920-14 A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection 2009-05-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-003289-16 A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or ... 2010-05-10 bad-data
Reported results 2007-004462-40 A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection wi... 2012-10-09 due-trials
Ongoing, reported early 2007-005281-12 A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 4 hepatitis C infection not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-007086-21 A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents 2011-08-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000533-22 A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copeg... 2010-07-16 bad-data
Ongoing 2008-001696-30 A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral naive HIV1 infected adolescents and ch... not-yet-due
No trial status on register 2008-004630-25 A Phase II, open label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV in combination with low-dose ritonavir (DRV/rtv) in treatment-experienced HIV-1 infected ... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004631-37 A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 yea... 2011-03-31 bad-data
Reported results 2008-005709-20 An open-label trial in genotype 2, 3, 4, 5 and 6 hepatitis C-infected subjects to evaluate the antiviral activity, safety, tolerability and pharmacokinetics of TMC435350 following 7 days once daily do... 2009-11-18 due-trials
Other 2008-006009-18 An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-007147-13 A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including peginterferon ... 2011-04-30 bad-data
Reported results 2008-008190-58 A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-admini... 2011-02-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-010590-20 A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a and... 2011-08-17 bad-data
Ongoing, reported early 2009-010887-41 A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combinatio... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-012613-21 An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21... 2012-05-16 bad-data
Ongoing 2009-013126-16 Acceso continuado de etravirina en niños y adolescentes infectados por VIH-1 previamente tratados. Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-017013-29 Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1 2017-11-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020444-36 A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2... 2013-01-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021113-23 A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2... 2013-02-04 bad-data
Reported results 2010-021174-11 A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2... 2013-02-05 due-trials
Ongoing 2010-021209-18 An open-label trial with TMC278 25 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected subjects, who participated in ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-021337-31 A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFN?-2a (Pegasys)® and ribavirin (Copegus)® triple therapy in chronic hepatitis C genotype-1 infected s... 2013-08-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021628-84 A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype... 2012-11-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000416-25 A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 stu... 2015-03-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-001180-53 A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFN?-2a and ribavirin, in chronic hepatitis C genoty... 2014-04-07 bad-data